RxDoctor Payments DataLook up a doctor →

Ferdinando Andrade, MD

Family Medicine · Omaha, NENPI 1548608573

Payments from drug & device makers

$8,743in general payments, 2019–2025

Across 370 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • AbbVie$803
  • Novo Nordisk$586
  • Bayer$445
  • Sanofi-aventis U.S. LLC$391
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,68999%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,743 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$82,619
Medicare patients
314
Services billed
2,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$109,245
JardianceEmpagliflozin117$104,153
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$54,553
EliquisApixaban38$45,087
TradjentaLinagliptin38$32,040
MounjaroTirzepatide22$26,727
LinzessLinaclotide34$26,705
MyrbetriqMirabegron32$25,654
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$23,716
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$17,233
Tresiba Flextouch U-100Insulin Degludec21$14,289
JanuviaSitagliptin Phosphate18$13,947
Breo ElliptaFluticasone/Vilanterol32$13,397
XareltoRivaroxaban15$12,781
TrulicityDulaglutide11$12,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$302$136,193155 claims
Novo NordiskOzempic$586$109,24599 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$183$95,825169 claims
PfizerEliquis$238$45,08738 claims
Lilly USA, LLCMounjaro, Trulicity$225$39,07733 claims
AbbVieLinzess, Synthroid$803$27,98749 claims
Astellas Pharma US IncMyrbetriq$80$25,65432 claims
Johnson & JohnsonXarelto$28$12,78115 claims
AstraZenecaSymbicort, Bevespi Aerosphere$1,867$10,53131 claims
Sanofi-aventis U.S. LLCLantus$391$2,17314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →